EFFECTS OF PRENYLATED ISOFlavONES OSAJIN AND POMIFERIN IN PREMEDICATION ON HEART ISCHEMIA-REPERFUSION

Tomas Florian\textsuperscript{a}, Jiri Necas\textsuperscript{a,*}, Lenka Bartosikova\textsuperscript{a}, Jarmila Klusakova\textsuperscript{c}, Vaclav Suchy\textsuperscript{b}, El Moataz B. El Naggar\textsuperscript{a}, Eva Janostikova\textsuperscript{a}, Tomas Bartosik\textsuperscript{c}

\textsuperscript{a} Department of Human Pharmacology and Toxicology, University of Veterinary and Pharmaceutical Sciences Brno, Pharmaceutical Faculty, Palackeho 1-3, 612 42 Brno, Czech Republic
\textsuperscript{b} Department of Natural Drugs, University of Veterinary and Pharmaceutical Sciences Brno, Pharmaceutical Faculty, Palackeho 1-3, 612 42 Brno, Czech Republic
\textsuperscript{c} St. Anne Teaching Hospital Brno, Czech Republic
e-mail: necasj@vfu.cz

Received: February 6, 2006; Accepted: March 22, 2006

Key words: Maclura pomifera/Isoflavones osajin and pomiferin/Heart ischemia-reperfusion/Free oxygen radicals

The present 15 days study was undertaken to evaluate the cardioprotective potential of the prenylated isoflavones osajin and pomiferin isolated from the infructences of \textit{Maclura pomifera}, Moraceae, against ischemia-reperfusion induced injury in rat hearts as a model of antioxidant-based composite therapy. The study was performed on isolated, modified Langendorff-perfused rat hearts and the ischemia of heart was induced by stopping coronary flow for 30 min followed by 60 min of reperfusion (14 ml min\textsuperscript{-1}). The Wistar rats were divided into four groups.

The first treatment group received osajin (5 mg/kg/day in 0.5% Avicel); the second treatment group received pomiferin (5 mg/kg/day in 0.5% Avicel); the placebo group received only 0.5 Avicel; the last was an untreated control group. Biochemical indicator of oxidative damage–lipid peroxidation product malondialdehyde, antioxidant enzymes – superoxide dismutase, glutathione peroxidase, total antioxidant activity in serum and myocardium were evaluated.

The effect of osajin and pomiferin on cardiac function, left ventricular end-diastolic pressure, left ventricular pressure and peak positive \(+\text{dP}/\text{dt}\) ischemia and reperfusion, also was examined.

The results demonstrate that osajin and pomiferin attenuates the myocardial dysfunction provoked by ischemia-reperfusion. This was confirmed by an increase in both antioxidant enzyme values and total antioxidant activity. The cardioprotection provided by osajin and pomiferin treatment results from the suppression of oxidative stress and this correlates with improved ventricular function.

INTRODUCTION

The flavonoids are a heterogeneous group of phenolic compounds (approx. 4000), ubiquitous in the plant kingdom. They normally occur in the human diet, especially in fruit and vegetables, and their daily intake is cca 1–2 g. Many positive as well as negative effects on plant and animal cells of flavonoids have been documented\textsuperscript{1–2}. Many of their effects are significant\textsuperscript{3–5}. In oncology the flavonoids are used as compounds, which reduce the side effects of cytostatics and on the other hand, they enhance the therapeutic effects. This field is documented very well\textsuperscript{6–8}.

Flavonoids are often used in the treatment of inflammation because of their ability to inhibit the key enzyme in PG (prostaglandins) synthesis – \textit{COX}\textsuperscript{9–11}. They have been tested in post-transplantation conditions too\textsuperscript{12–13}.

Flavonoids are effective antioxidants in the case of the oxidative injury\textsuperscript{14–15}. They prevent lipid peroxidation, scavenge free oxygen radicals and inactivate pro-oxidative metal ions (iron, copper). The scavenging activity is one of the best-known properties and it represents a significant therapeutic use\textsuperscript{16–17}. The antioxidant activity of the flavonoids depends on the number and position of hydroxyl groups in their molecules and on their glycosylation. Optimal properties were found in flavonoids with an ortho-hydroxy structure on ring B; 2, 3 double bond, and 4-oxo functional group in the ring C, and 3 and 5 -OH groups on the rings A and C\textsuperscript{18}.

In vitro studies of antioxidant abilities of osajin and pomiferin have revealed: the peroxinitrite and DPPH (diphenyl-picryl-hydrazyl) radical scavenging activity. The Fe(II)/NADPH enhanced lipid peroxidation test in the rat liver microsomal fraction was also performed. Mouse hepatic microsomes were used to determine the EROD activity (7-ethoxyresorufin-O-deethylase) of osajin and pomiferin\textsuperscript{19}.

Among various reactive oxygen species (ROS) generated during pathological processes, which cause or accompany ischemia/reperfusion (I/R) injury, O\textsuperscript{2−} plays the key role. In spite of being a free radical, it is not highly reactive. However the O\textsuperscript{2−} radical anion appears to play a central role, since other reactive intermediates are formed in a reaction sequences starting with it. Since the physio-
logical functions of heart are conditioned by a remarkable consumption of oxygen, the elimination of O\textsuperscript{2-} radical during I/R is one possible therapeutic intervention. In the presented study we have examined whether it is possible to affect the origination of O\textsuperscript{2-} and its metabolic derivates experimentally during the heart I/R secondary to the 15 days oral administration (5 mg/kg/day) of flavonoids osajin or/and pomiferin.

MATERIAL AND METHODS

Extract preparation

Ground fruit of Maclura pomifera, Moraceae, was subjected to consecutive Soxhlet extraction using methanol, yield yellow crystals of osajin-pomiferin mixture after cooling. The crystals were filtered, washed and dissolved in hot methanol.

Pomiferin was separated from osajin by the addition of lead acetate which reacts with the two hydroxyl groups at position 3 and 4 on ring B of pomiferin to form a light yellow insoluble coagulate while osajin remains in solution since it has only one hydroxyl group on ring B. Osajin was then further re-crystallized from the methanolic solution after concentration under vacuum.

Separation procedure

10 grams of osajin/pomiferin crystals were dissolved in 200 ml of hot methanol and then mixed with 15 grams of lead acetate trihydrate (dissolved in 20 ml methanol). The light yellow coagulate created over night was filtered and then rinsed with hot acetone.

Osajin and pomiferin were obtained by re-crystallization from the thickened methanol and acetone solutions.

For the purpose of identification and purity ascertainment of osajin and pomiferin during all the extraction process, reversed phase high performance liquid chromatography was performed.

Reversed phase high performance liquid chromatography

The HPLC (HP 1100) system consists of quaternary pump, autosampler, thermostatic column compartment, and diode array detector. The analytical column was Supelcosil ABZ+Plus and LC-8, 15 cm × 4.6 mm, 3μm. The mobile phase consisted of two eluents, (A) acetonitrile and (B) 40 mM formic acid. Separation of compounds was carried out with gradient elution profile: 1st min, 70 : 30, during 15 min, 100 : 0. Chromatography was performed at 40 °C with a flow-rate of 1.0 ml/min, and detection was at 280 nm and 350 nm.

Animals and therapy

The study and its experimental protocol were approved and monitored by the Ethics Committee of the University of Veterinary and Pharmaceutical Sciences in Brno. The state of health of all animals was inspected regularly several times a day both during the acclimation of the animals and in the course of the whole experiment performed by the work group whose members are holders of the Eligibility Certificate issued by the Central Commission for Animal Protection pursuant to Section 17 of the Czech National Council Act No 246/1992 Coll. on animal protection against maltreatment.

This study was performed on 40 male Wistar SPF (AnLab, Germany) laboratory rats of identical age (6 month) and comparable weight (354 ± 27 gr). The animals were housed at a standard controlled temperature, fed a standard diet for small laboratory animals, and given water ad libitum. After a recovery period, the animals were divided randomly into 4 groups (ten rats in each group):

The first group-received osajin daily at a dose of 5 mg.kg\textsuperscript{-1} in 2 ml of 0.5% Avicel solution orally by intragastric tube, the second-treatment group-received pomiferin daily at a dose of 5 mg.kg\textsuperscript{-1} in 2 ml of 0.5% Avicel solution orally by intragastric tube\textsuperscript{2}. The third - the placebo group - received only 0.5% Avicel in the same quantity (2 ml) and by the same application method as in the treated group. The last group of the animals received no treatment or Avicel.

Experimental design

At the end of the treatment period (15 days) rats were anesthetized with an intraperitoneal injection of anaesthetic (2% Rometar 0.5 ml + 1% Narkamon 10 ml, dose 0.5 ml solution/100 g body weight) and after intraperitoneal administration of heparine injection of 500 IU dose, the heart were excised and perfused. In all experiment, modified Langendorff method and the universal apparatus Hugo Sachs Electronic UP 100 (Germany HSE) was used. Working schedule: stabilization/ischemia/reperfusion proceeded at intervals of 10/30/60 min. The evaluated blood biochemical parameters: malondialdehyde (MDA) serum values – TBARs method, total antioxidant activity (TAA), glutathion peroxidase (GSHPx), superoxide dismutase (SOD), using RANODX testing kits (Dublin, Ireland).

Biomechanical parameters from isolated heart: left ventricle pressure (LVP), end-diastolic pressure (LVEDP),
Effects of prenylated isoflavones osajin and pomiferin in premedication on heart ischemia-reperfusion

Fig. 2. High-performance liquid chromatogram of osajin from infructescence of *Maclura pomifera*, Moraceae. (LC-8 – method Maclura).

Fig. 3. High-performance liquid chromatogram of pomiferin from infructescence of *Maclura pomifera*, Moraceae (Supelcosil ABZ+Plus, method Muscar).

contractility (dP/dt<sub>max</sub>) were measured using a ball filled with liquid (8–12 mmHg), inserted through the left atrium in the left ventricle connected to the analog convertor (Isotec HSE, DIF modul HSE)\textsuperscript{23}. After reperfusion, the heart was cooled in liquid nitrogen and stored at a temperature –80 °C for further analyses. Lipoperoxidation assessment: in supernatant of the heart homogenizer in saline, the TBARS value was assessed by the spectroscopic method\textsuperscript{24}. Antioxidant enzyme activities: cellular GSH peroxidase (GSHPx) activity\textsuperscript{25–26}, cellular SOD activity\textsuperscript{27–28}. 
Table 1. Effect of osajin and pomiferin application on MDA serum values, total antioxidant activity and activity of enzymes participating in scavenging reactions.

<table>
<thead>
<tr>
<th>Animal groups (n = 10)</th>
<th>MDA (mmol/L)</th>
<th>TAA (mmol/L)</th>
<th>SOD (U/ml)</th>
<th>GSHPx (μkat/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated with osajin (5 mg/kg/day)</td>
<td>0.80 ± 0.08 ** ++</td>
<td>0.49 ± 0.03 ** ++</td>
<td>232.23 ± 17.62 ** ++</td>
<td>1569.48 ± 133.93 ** ++</td>
</tr>
<tr>
<td>Treated with pomiferin (5 mg/kg/day)</td>
<td>0.89 ± 0.11 ** ++</td>
<td>0.52 ± 0.05 ** ++</td>
<td>227.98 ± 19.21 ** ++</td>
<td>1619.81 ± 146.23 ** ++</td>
</tr>
<tr>
<td>Placebo group</td>
<td>1.77 ± 0.12</td>
<td>0.41 ± 0.04</td>
<td>70.39 ± 2.79</td>
<td>1229.10 ± 120.45</td>
</tr>
<tr>
<td>Control group</td>
<td>1.89 ± 0.16</td>
<td>0.43 ± 0.03</td>
<td>67.37 ± 3.97</td>
<td>1121.37 ± 152.21</td>
</tr>
</tbody>
</table>

** p ≤ 0.01 treated vs placebo group
++ p ≤ 0.01 treated vs control group

Table 2. Values of myocardial MDA, and activity GSHPx and SOD.

<table>
<thead>
<tr>
<th>Animal groups (n=10)</th>
<th>MDA (nmol/mg protein)</th>
<th>GSHPx (nmol/min/mg protein)</th>
<th>SOD (U/mg protein)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treated with osajin (5 mg/kg/day)</td>
<td>2.67 ± 0.21 ** ++</td>
<td>62.0 ± 2.5</td>
<td>6.7 ± 0.5 * +</td>
</tr>
<tr>
<td>Treated with pomiferin (5 mg/kg/day)</td>
<td>3.26 ± 0.23 * +</td>
<td>63.1 ± 2.3</td>
<td>6.4 ± 0.6 * +</td>
</tr>
<tr>
<td>Placebo group</td>
<td>4.55 ± 0.15</td>
<td>65.5 ± 5.0</td>
<td>5.6 ± 0.6</td>
</tr>
<tr>
<td>Control group</td>
<td>4.71 ± 0.19</td>
<td>68.0 ± 4.0</td>
<td>5.8 ± 0.7</td>
</tr>
</tbody>
</table>

** p ≤ 0.01 treated vs placebo group
++ p ≤ 0.01 treated vs intact group
* p ≤ 0.05 treated vs placebo group
+ p ≤ 0.05 treated vs intact group

Preparation of rat heart homogenate and measured biochemical parameters

Tissue homogenate was prepared in a ratio of 1 g of wet tissue to 10 times (w/v) 0.05 M-ice cold phosphate buffer (ph 7.4) and homogenized using DI 25 Basic, Germany homogenizer. Myocardial thiobarbituric acid reactive substances (TBARS) a marker of lipid peroxidation, and endogenous antioxidants e.g. superoxide dismutase (SOD) and glutathione peroxidase (GSHPx) were measured in all the groups.

Lipid peroxidation assay

The lipid peroxidation was assessed by studying thiobarbituric acid reactive substances (TBARS) by the method described by Buege and Aust24. Aliquots of the supernatant were added to a pyrex tube that contained trichloracetic acid (10 %) and thiobarbituric acid (0.67 %) and incubated at 100 °C for 15 minutes. The mixture was allowed to cool on ice for 5 min. This was followed by the addition of 1.5 ml of butyl-alcohol; the mixture was vigorously agitated for 40 s and centrifuged at 1000 g for 15 min to extract the resulting chromogen. The TBARS value was assessed by the spectroscopic method (spectrophotometer Unicam UV 300, GB) at absorbance 532 nm and calculated using the coefficient 1.56 x 105 M–1 cm–1, expressed as nmol MDA/g of tissue. Commercially available malondialdehyde was used as a standard.

Antioxidant enzyme activities

Assay of cellular GSH peroxidase activity.
Cellular GSH peroxidase (GSHPx) activity was measured by the method of Flohé and Gunzler25 and Kakkar26. Briefly, to an assay cuvette containing 0.5 ml of 50mM potassium phosphate (pH 7.0), 1mM EDTA, and 2mM sodium azide, 100 μl of sample, 100 μl of 10mM GSH, 100 μl of glutathione reductase (2.4 U/ ml), and 100 μl of 1.5mM NADPH were added. The cuvette was incubated at 37 °C for 3 min. After the addition of 100 μl of 2mM H2O2, the rate of NADPH consumption was monitored at 340 nm, 37 °C for 5 min. This was designated as the total rate of NADPH consumption. The non-enzyme dependent consumption of NADPH was also measured.
as above except that the 100 μl of sample was replaced by 100 μl of sample buffer. The rate of enzyme-dependent NADPH consumption was obtained by subtracting the non-enzyme-dependent NADPH consumption rate from the total NADPH consumption rate. GSHPx activity was calculated using the extinction coefficient of 6.22 mM−1 cm−1 and expressed as nanomoles of NADPH consumed per min per milligram of cellular protein.

**Assay of cellular SOD activity.**

Total cellular SOD activity was determined by the method of Spitz and Oberley27 with slight modifications by Wendel28. Briefly, the reaction mix (to be prepared freshly) contained in 50mM potassium phosphate buffer, pH 7.8, 1.33mM diethylenetriaminepentaacetic acid, 1.0 U/ml catalase, 70 μM nitroblue tetrazolium, 0.2mM xanthine, 0.05mM bathocuproinedisulfonic acid, and 0.13 mg/ml BSA. As much as 0.8 ml of the reaction mix was added to each cuvette, followed by addition of 100 μl of sample. The cuvettes were pre-warmed at 37 °C for 3 min. The reaction was then started by adding 100 μl of XO (0.1 U/ml). The formation of formazan blue was monitored at 560 nm, 37 °C for 5 min. The reaction was then started by adding 100 μl of XO (0.1 U/ml). The formation of formazan blue was monitored at 560 nm, 37 °C for 5 min. The sample total SOD activity was calculated using a concurrently run SOD (Sigma Chemical) standard curve and expressed as units per milligram of cellular protein.

**Statistical analysis**

The obtained values of the studied biochemical parameters were processed by the Microsoft® Excel table processor and statistically evaluated using UNISTAT programme, ANOVA test and unpaired Student’s t-test. All values are expressed as mean ± SE. Statistical differences with a value p ≤ 0.05 were considered significant.

**RESULTS**

**Biochemical results – blood**

After the oral administration of osajin and pomiferin for a period of 15 days, MDA values were found to be significantly (p ≤ 0.01) decreased in treated groups compared to the placebo or control animal groups (0.80 ± 0.08 and 0.89 ± 0.11 v.s. 1.77 ± 0.12 and 1.87 ± 0.16).

The serum TAA values were significantly (p ≤ 0.01) reduced in the placebo and control animal groups in comparison to that of the osajin and pomiferin-treated groups (0.41 ± 0.04 and 0.43 ± 0.03 v.s. 0.49 ± 0.03 and 0.52 ± 0.05). The results of MDA and TAA assays are summarized in the Table 1.

The superoxide dismutase (SOD) values were significantly (p ≤ 0.01) highly increased in the treated animals groups compared to the placebo or control animal groups (232.23 ± 17.62 and 227.98 ± 19.21 v.s. 70.39 ± 2.79 and 67.37 ± 3.97).

The GSHPx values were significantly (p ≤ 0.01) increased in the treated animals compared to that of the placebo or control animal groups (1569.48 ± 133.93 and 1619.81 ± 146.23 v.s. 1229.10 ± 120.45 and 1121.37 ± 152.21). The results of SOD and GSHPx assays are summarized in the Table 1.

**Biochemical results – heart**

Myocardial MDA, activity of myocardial GSHPx and activity of myocardial SOD

There was a significant decrease in myocardial MDA in osajin (p ≤ 0.01) and pomiferin (p ≤ 0.05) treated groups compared to that of placebo or control groups (2.67 ± 0.21 and 3.26 ± 0.23 v.s. 4.55 ± 0.15 and 4.71 ± 0.19 nmol/mg protein). No significant change was noted in myocardial MDA between placebo and control groups (4.55 ± 0.15 vs. 4.71 ± 0.19 nmol/mg protein).

There was no significant change in myocardial GSHPx activity between treated, placebo and control groups respectively (62.0 ± 2.5 and 63.1 ± 2.3 v.s. 65.5 ± 5.0 and 68.0 ± 4.0).

There was a significant (p ≤ 0.05) reduction in myocardial SOD activity in placebo or control group when compared to that of treated group (5.6 ± 0.6 and 5.8 ± 0.7 v.s. 6.7 ± 0.5 and 6.4 ± 0.6 units/mg protein). No significant change was noted in myocardial SOD between placebo and control group (5.6 ± 0.6 vs. 5.8 ± 0.7 units/mg protein).

**Biomechanical results**

Fig. 4 shows the effect of osajin and pomiferin on LVP during ischemia and reperfusion. In hearts from placebo and control animals LVP recovered to 64 ± 7 and 65 ± 6 % of preischemic values at the end of the reperfusion. While hearts from the osajin and pomiferin pretreated animals, showed significantly improved postischemic recovery, reaching LVP values of 98 ± 8 % and 96 ± 8 % at the end of the reperfusion.

Fig. 5 shows the changes elicited in the osajin and pomiferin pretreated animals. In hearts from placebo and control animals LVEDP rise from 10.0 ± 0.5 mmHg to 44 ± 3 and 43 ± 4 mmHg after 60 min of reperfusion. This increase was diminished in the hearts of the osajin and pomiferin pretreated animals. LVEDP was only 30 ± 2 and 32 ± 2 mmHg at the end of reperfusion.

Fig. 6 shows the effect of osajin and pomiferin on dP/dt\(_{max}\) during ischemia and reperfusion. The pretreatment with osajin and pomiferin improved +dP/dt\(_{max}\) recovery during reperfusion to 93 ± 4 % and 91 ± 10 % at 60 min of reperfusion. These values were significantly greater than those obtained from the placebo and control hearts (73 ± 5 and 72 ± 4 %).

**DISCUSSION**

All biological systems are permanently in contact with reactive oxygen or nitrogen species (ROS/RNS) – so-called free radicals. These come from external sources or originate endogenously during physiological processes. The delicate balance between the cellular antioxidant defence and the generation of ROS is important for maintaining homeostasis. An imbalance in the oxidant-antioxidant ac-
Oxidative stress is a condition in which the production of reactive oxygen species (ROS) is increased, leading to damage of cells and tissues. ROS play an important role in the pathogenesis of ischemia/reperfusion (I/R) injury to the heart. Oxygen is critical to myocardial cell aerobic metabolism and maintenance of high-energy stores for normal myocardial function. Acute ischemia results in a spectrum of disorders, which range from transient reversible stunning of the myocardium, to severe irreversible abnormalities. Ischemia-reperfusion injury is a complex process; the excessive production of oxygen-free radicals is the main mechanism involved in I/R injury. In the heart, oxygen radicals may be generated by several mechanisms, such as mitochondrial respiration, activated neutrophils and, in some species, by xanthine oxidase activity. The release of free radicals (O–2● and OH–●) in the early phase of reperfusion, in combination with the I/R-induced decrease in antioxidant activity, renders the myocardium extremely vulnerable. The fact that the free oxygen radicals play a significant role during the heart I/R is well known, being accompanied by SOD, GSHPx depletion and reduction of TAA which acts as natural oxygen radical scavengers in the organism.

The aim of the performed study was assessment of the cardioprotective effect of the flavonoids osajin and pomiferin separated from *Maclura pomifera*, Moraceae. The effects of osajin and pomiferin were studied on ischemia-reperfusion injury in rats as a model of antioxidant-based composite therapy.

Antioxidant protection under conditions of induced oxidative injury is a complex system in which the separate antioxidant elements co-operate with one another. The function of one antioxidant often conditions the effects of another element in the system. Dismutation of O–2● by SOD is the first step of the enzymatic cascade leading to the complete detoxification of free radicals. However, the product of its activity, H2O2, is still a toxic agent. The second step corresponds to the transformation of H2O2 to H2O via hydroperoxidases such as catalase or glutathione peroxidase (GSHPx).

The superoxide dismutase (SOD) serum values were statistically highly significantly (p ≤ 0.01) increased in the treated animals compared to that of the placebo and control animal groups (232.23 ± 17.62 and 227.98 ± 19.21 v.s. 70.39 ± 2.79 and 67.37 ± 3.97). There was a significant (p ≤ 0.05) reduction in myocardial activity of SOD in placebo and control group compared to that of the treated group (6.7 ± 0.5 and 6.4 ± 0.6 v.s. 5.6 ± 0.6 and 5.8 ± 0.7 units/mg protein). No significant change was noted in myocardial SOD between placebo and control groups (5.6 ± 0.6 vs. 5.8 ± 0.7 units/mg protein).

It is evident that the increase of the SOD activity can be noxious for the organism. Since it can produce H2O2 (a precursor of the hydroxyl radical) at a rate in excess of that at which hydroperoxidases can remove it.

The GSHPx values were highly significantly (p ≤ 0.01) increased in the treated animals in comparison with the placebo and the control animal groups (1569.48 ± 133.93 and 1619.81 ± 146.23 v.s. 1229.10 ± 120.45 and 1121.37 ± 152.21). There were no significant changes in myocardial GSHPx activity in the treated, placebo or control animal groups, respectively (62.0 ± 2.5 and 63.1 ± 2.3 v.s. 65.5 ± 5.0 and 68.0 ± 4.0).

GSHPx is only able to act in the presence of sufficient amount of reduced glutathione (GSH). GSH is oxidized to GSGG, and then GSGG (oxidized glutathione) can be reduced to (GSH) by the NADPH-dependent flavoenzyme glutathione reductase in order to maintain GSHPx activity. Thus, the ratio of GSSG to GSH is believed to be an excellent antioxidant marker during intracellular oxidative stress.

Natural antioxidants can react with various radicals through different mechanisms; they can affect one an-
other (synergy, inhibition). Therefore we measured the total antioxidant activity, which quantifies the capacity of radical elimination in a biological material sample. After 15 days of osajin and pomiferin per-oral administration the total antioxidant activity serum values were statistically significantly (p ≤ 0.01) reduced in the placebo and control animal groups in comparison with the treated groups (0.41 ± 0.04 and 0.43 ± 0.03 v.s. 0.49 ± 0.03 and 0.52 ± 0.05).

After the 15 days oral administration of osajin and pomiferin at the dose of 5 mg/kg, the serum MDA values were significantly (p ≤ 0.01) decreased in treated groups compared to that of the placebo and control animals (0.80 ± 0.08 and 0.89 ± 0.11 vs. 1.77 ± 0.12 and 1.89 ± 0.16).

MDA, as a final product and a marker of free hydrogen radical metabolism generated during the pathological reactions following I/R, was significantly (p ≤ 0.01; p ≤ 0.05) reduced in the myocardium of the osajin and pomiferin treated groups compared to that of placebo and control group (2.67 ± 0.21 and 3.26 ± 0.23 v.s. 4.55 ± 0.15 and 4.71 ± 0.19 nmol/mg protein). No significant changes were observed in the myocardial levels of MDA between placebo and control groups (4.55 ± 0.15 v.s. 4.71 ± 0.19 nmol/mg protein).

Our results confirmed that there was a significant decrease in the myocardial MDA values in osajin and pomiferin treated groups compared to that of the placebo and control animal groups by which it confirmed the capacity to prevent liperoxidation induced by I/R injury.

The findings from serum and myocardium supported the functional changes in treated hearts in comparison with placebo and control groups.

In hearts from placebo and control animals LVP recovered to 64 ± 7 and 65 ± 6 % of preischemic values at the end of the reperfusion. In the osajin and pomiferin pre-treated animals the hearts showed significantly improved postischemic recovery, reaching LVP values of 98 ± 8 and 96 ± 8 % at the end of the reperfusion.

In hearts from placebo and control animals LVEDP rose from 10.0 ± 0.5 to 44 ± 3 and 43 ± 4, respectively mmHg after 60 min of reperfusion. This increase was diminished in the hearts from the osajin and pomiferin pretreated animals to 30 ± 2 and 32 ± 2 mmHg at the end of reperfusion.

The pretreatment with osajin and pomiferin improved +dP/dt max recovery during reperfusion to 93 ± 4 and 91 ± 10% at 60 min of reperfusion. These values were significantly greater than those obtained from placebo and control hearts (73 ± 5 and 72 ± 4 %).

From the results of our experiment it can be deduced that the administration of osajin and pomiferin in laboratory rats has a cardioprotective potential against ischemia-reperfusion induced injury in rat hearts as a model of antioxidant-based composite 15 days therapy. This was confirmed by the increase in both the antioxidant enzyme values and the total antioxidant activity that occur even at the dose 5 mg/kg/day. This effect is also demonstrated in the functional parameters of hearts – LVP, LVEDP, and +dP/dt max.

In conclusion, the results from the present study suggest that the prenylated isoflavones osajin and pomiferin have a potent cardioprotective effects in prefused rat hearts subjected to global ischemia and reperfusion. Its effects may be mediated through the inhibition of lipid peroxidation.

Isoflavones osajin and pomiferin can antagonize myocardial injury induced by I/R through inhibiting oxidative stress. In this work, pre-treatment with osajin and/or pomiferin at the doses of 5 mg/kg/day, significantly decreased the myocardial lipid peroxide production of MDA and indicated that osajin and pomiferin could have an inhibiting effect on oxidative stress induced by I/R. Although the isoflavones osajin and pomiferin seem to be protective with a probable effect against the oxidative injury induced by the heart I/R, their effects and optimal method of application have to be explored further.

REFERENCES